Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Addressing Avonex Liquid Formulation Manufacturing Problems

This article was originally published in The Pink Sheet Daily

Executive Summary

Pre-filled syringe process is experiencing a "technical issue" on the fill-finish side. Biogen has the option to ramp up production of Avonex' original lyophilized powder formulation to make up for shortages on the liquid side.

You may also be interested in...



Avonex Syringe Component Approval Is "Good News" Despite Charge, Biogen Idec Says

FDA's approval in March of a new component for the pre-filled syringe is "good news" for the MS therapy but resulted in a first quarter charge of $11 mil. for finished product that is no longer needed, the company says. Avonex sales grew 5.4% during the quarter, driven by international gains.

Avonex Syringe Component Approval Is "Good News" Despite Charge, Biogen Idec Says

FDA's approval in March of a new component for the pre-filled syringe is "good news" for the MS therapy but resulted in a first quarter charge of $11 mil. for finished product that is no longer needed, the company says. Avonex sales grew 5.4% during the quarter, driven by international gains.

Avonex Manufacturing Update: New Liquid Fill-Finish Process Validated

Biogen Idec has completed validation of a new fill-finish process for the liquid formulation of Avonex.

Topics

UsernamePublicRestriction

Register

PS058980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel